Journal of Clinical and Aesthetic Dermatology

Plaque-type Psoriasis Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/691107

Contents of this Issue

Navigation

Page 15 of 15

S16 SUPPLEMENT TO THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY [JUNE 2016 • VOLUME 9 • NUMBER 6 • SUPPLEMENT 1] Rheum Dis. 2013;72(Suppl 2):ii116–123. 2. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid a rthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. 3. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. 4. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo- controlled, phase II regimen-finding study. Br J Dermatol. 2 013;168(2):402–411. 5. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. 6. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82(3):192–195. 7. Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health- related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623–632. 8. Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–275. 9. Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails. Curr Probl Dermatol. 2009;38:160–171. 10. Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–1408. 11. Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol. 2013;27(3):e384–e389. 12. Gottlieb A, Sullivan J, van Doorn M et al. Secukinumab is effective in subjects with moderate to severe palmoplantar psoriasis: 16 week results from the GESTURE study. Presented at: 23rd World Congress of Dermatology; Vancouver, Canada; 11 June 2015. 13. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1): 1–27. 14. Radtke MA, Beikert FC, Augustin M. Nail psoriasis—a treatment challenge. J Dtsch Dermatol Ges. 2013;11(3): 203–219; quiz 220. 15. Dalbeth N, Pui K, Lobo M, et al. Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis. J Rheumatol. 2012;39(4):841–843. 16. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol. 2010;39(4):299–302. 1 7. Ivanov S, Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30(2):95–103. 18. Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 week results from the TRANSFIGURE study. Presented at: 23rd World Congress of Dermatology; Vancouver, Canada; June 8–15, 2015. 19. Mason AR, Mason JM, Cork MJ, et al. Topical treatments for c hronic plaque psoriasis of the scalp: a systematic review. Br J Dermatol. 2013;169(3):519–527. 20. Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016;2: CD009687. 21. Frez ML, Asawanonda P, Gunasekara C, et al. Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group. J Dermatolog Treat. 2014;25(1):38–45. 22. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6): 962–971. 23. Kircik LH, Kumar S. Scalp psoriasis. J Drugs Dermatol. 2010;9(8 Suppl ODAC Conf Pt 2):s101–s105. 24. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448–459. 25. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to- treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142. 26. Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double- blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67(1):86–92. 27. Thaçi D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–360. 28. Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, et al. Evidence-based guidelines of the Spanish Psoriasis Group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles). Actas Dermosifiliogr. 2014;105(10):923–934. 29. Lebwohl M, Qureshi A, Kianifard F, et al. Secukinumab in the treatment of moderate-to-severe scalp psoriasis: a study to evaluate efficacy and safety. Presented at: American Academy of Dermatology, 73rd Annual Meeting; San Francisco, CA: March 20–24, 2015. 30. Imafuku S, Shima T, Ito S, et al. Efficacy and safety of secukinumab in Japanese patients with generalized pustular psoriasis. Presented at: 23rd World Congress of Dermatology; Vancouver, Canada; June 8–15, 2015.

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Plaque-type Psoriasis Supplement 2016